Jim advises technology and life sciences companies, investors, and executives on a broad range of executive compensation and employee benefits matters. He has extensive experience supporting clients at all stages of growth—from early-stage startups to mature public companies—with a particular focus on the unique needs of emerging companies navigating rapid scale, IPO readiness, and complex M&A events.

Jim regularly counsels boards, compensation committees, and management teams in the technology, biotech, and digital health sectors on the design and implementation of employment, retention, and change in control arrangements. He also works closely with venture capital and private equity firms on structuring executive compensation programs for portfolio companies, with specialized insight into ERISA Title I compliance. In addition, Jim represents C-suite executives and founding teams as they negotiate compensation terms during hiring, exit, and transactional events.

With a strong background in tax, Jim offers sophisticated guidance on key regulatory issues, including Sections 280G and 409A, and equity compensation strategies tailored to high-growth, innovation-driven businesses. He is particularly adept at aligning compensation structures with investor expectations and business goals during strategic inflection points.

He has been recognized in Best Lawyers in America for Employee Benefits (ERISA) Law every year since 2013.